EE9900345A - Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks - Google Patents

Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks

Info

Publication number
EE9900345A
EE9900345A EEP199900345A EE9900345A EE9900345A EE 9900345 A EE9900345 A EE 9900345A EE P199900345 A EEP199900345 A EE P199900345A EE 9900345 A EE9900345 A EE 9900345A EE 9900345 A EE9900345 A EE 9900345A
Authority
EE
Estonia
Prior art keywords
glitazone
sulfonylurea
diabetes
treatment
synergistic combinations
Prior art date
Application number
EEP199900345A
Other languages
English (en)
Inventor
W. Whitcomb Randall
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9900345A publication Critical patent/EE9900345A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP199900345A 1997-02-19 1997-12-01 Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks EE9900345A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (1)

Publication Number Publication Date
EE9900345A true EE9900345A (et) 2000-02-15

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900345A EE9900345A (et) 1997-02-19 1997-12-01 Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks

Country Status (29)

Country Link
US (2) US5859037A (et)
EP (1) EP0957923A1 (et)
JP (1) JP2001512478A (et)
KR (1) KR20000071179A (et)
CN (1) CN1244801A (et)
AR (1) AR011829A1 (et)
AU (1) AU741215B2 (et)
BG (1) BG103671A (et)
BR (1) BR9714505A (et)
CA (1) CA2272478A1 (et)
CZ (1) CZ289299A3 (et)
EA (1) EA199900725A1 (et)
EE (1) EE9900345A (et)
GT (1) GT199800037A (et)
HN (1) HN1997000167A (et)
HU (1) HUP0001528A3 (et)
IL (1) IL130027A (et)
IS (1) IS5058A (et)
NO (1) NO993982D0 (et)
NZ (1) NZ336002A (et)
PA (1) PA8447401A1 (et)
PE (1) PE74399A1 (et)
PL (1) PL335166A1 (et)
SK (1) SK111899A3 (et)
SV (1) SV1998000010A (et)
TR (1) TR199902033T2 (et)
UY (1) UY24893A1 (et)
WO (1) WO1998036755A1 (et)
ZA (1) ZA981343B (et)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
TR199903057T2 (xx) * 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
EP1671637A3 (en) * 1997-06-18 2007-12-19 SmithKline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
WO2000038666A2 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
WO2000055318A2 (en) * 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
DE60103203T2 (de) * 2000-04-13 2005-05-04 Pfizer Products Inc., Groton Synergistische Wirkung von Glyburide und Milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
TWI339586B (en) 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
EP1937716A2 (en) * 2005-09-08 2008-07-02 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
WO2007072992A2 (en) 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CA3123813C (en) 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CN108191846B (zh) 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
KR101701943B1 (ko) * 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
CA2806619C (en) 2010-05-24 2018-05-22 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
KR102584819B1 (ko) 2011-01-19 2023-10-05 프랙틸 헬쓰, 인코포레이티드 조직의 치료를 위한 장치 및 방법
US9737559B2 (en) 2011-11-23 2017-08-22 Ozstar Therapeutics Pty Ltd Synergistic anti-diabetic compositions
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
EP4066764A1 (en) 2012-02-27 2022-10-05 Fractyl Health, Inc. Heat ablation systems and devices for the treatment of tissue
CA2869904C (en) 2012-04-19 2020-04-21 Fractyl Laboratories, Inc. Systems for expanding tissue prior to energy ablation
WO2014022436A1 (en) 2012-07-30 2014-02-06 Fractyl Laboratories Inc. Electrical energy ablation systems, devices and methods for the treatment of tissue
EP2882362B1 (en) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
KR102284469B1 (ko) 2013-11-22 2021-08-02 프랙틸 헬쓰, 인코포레이티드 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
EP3169260B1 (en) * 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12403138B2 (en) * 2019-11-22 2025-09-02 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
WO2021146535A1 (en) 2020-01-15 2021-07-22 Fractyl Laboratories, Inc. Automated tissue treatment devices, systems, and methods
WO2021262646A1 (en) 2020-06-22 2021-12-30 Fractyl Health, Inc. Tissue treatment system with fluid delivery console

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
HN1997000167A (es) 1999-02-09
US5972973A (en) 1999-10-26
IS5058A (is) 1999-05-27
KR20000071179A (ko) 2000-11-25
EA199900725A1 (ru) 2000-04-24
PL335166A1 (en) 2000-04-10
US5859037A (en) 1999-01-12
NZ336002A (en) 2002-03-28
AR011829A1 (es) 2000-09-13
JP2001512478A (ja) 2001-08-21
PE74399A1 (es) 1999-08-20
CA2272478A1 (en) 1998-08-27
UY24893A1 (es) 1998-07-10
SK111899A3 (en) 2000-09-12
WO1998036755A1 (en) 1998-08-27
AU741215B2 (en) 2001-11-29
ZA981343B (en) 1998-11-16
EP0957923A1 (en) 1999-11-24
SV1998000010A (es) 1999-02-02
NO993982L (no) 1999-08-18
IL130027A0 (en) 2000-02-29
AU5590898A (en) 1998-09-09
TR199902033T2 (xx) 2000-02-21
HUP0001528A3 (en) 2000-12-28
BG103671A (en) 2000-04-28
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
CZ289299A3 (cs) 1999-11-17
NO993982D0 (no) 1999-08-18
BR9714505A (pt) 2000-03-21
IL130027A (en) 2005-09-25
CN1244801A (zh) 2000-02-16
PA8447401A1 (es) 2001-12-14

Similar Documents

Publication Publication Date Title
NO993982D0 (no) Synergistiske sulfonylurea-glitazone-kombinasjoner for diabetes
EP0708615A4 (en) DEVICE FOR BLOODY MONITORING OF THE GLUCOSE CONTENT
AT503376A3 (de) Synergistische spot-on-formulierung
FI964314A7 (fi) Substituoidut sulfonamidit selektiivisinä beta3-agonisteina diabeteksen ja liikalihavuuden hoitoon
FI943745L (fi) Koostumuksia ja menetelmiä proteiinin rakenteen määrityksiin
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
DE69522843D1 (de) Knochenanker
NO983266D0 (no) Distribuert Behandling
ID22878A (id) Komposisi aktif secara terapi
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
FI961630A7 (fi) Terapeuttisia aineita
DE69504051D1 (de) Synergistisches entlackungsmittel
ID15967A (id) Agen terapi diabetes
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
FI964267A7 (fi) Porfosyaniini ja CNC-laajennetut porfyriinit
DE69727738D1 (de) Piezoelektrisches Bauelement
NO983263D0 (no) Distribuert behandling
IT1276653B1 (it) Componente multistrato
FR2749945B1 (fr) Composant electrooptique
ATE353654T1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
ATE366577T1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
DE69724869D1 (de) Piezoelektrisches Bauelement
DE59812720D1 (de) Verwendung von phytostenol enthaltender wirkstoffmischungen zur herstellung von hypocholesterinämischen mitteln
PT970080E (pt) Derivados de imino-aza-antraciclinona para o tartamento de amiloidoses
DK0734514T3 (da) Vævsprøvebehandling